SIGMAR1 (Open Access article) (G10280)

Target Name: SIGMAR1

NCBI ID: G10280

SIGMAR1

SIGMAR1 (Open Access article)

Sigmar1 (Signal transducer and activation-regulated gene 1) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 12 and encodes a protein known as SIGMAR1, which is involved in the intracellular signaling pathway known as the NF-kappa pathway.

The NF-kappa pathway is a well-established pathway that plays a crucial role in the development and maintenance of tissues and organs, as well as in the regulation of cellular processes such as cell growth, differentiation, and inflammation. The pathway is composed of several transcription factors, including NF-kappa1, which is a key regulator of the pathway, and its downstream targets, such as SIGMAR1.

SIGMAR1 is a 21-kDa protein that is expressed in a variety of tissues and cells, including pancreatic cancer, breast cancer, lung cancer, and neurobladder cancer. It is involved in the regulation of NF-kappa1 signaling and has been shown to play a role in the development and progression of these diseases.

SIGMAR1 has also been shown to be involved in the regulation of cellular processes that are relevant to various diseases, including cancer. For example, studies have shown that SIGMAR1 can be involved in the regulation of cell cycle progression, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

In addition to its role in disease, SIGMAR1 is also a potential biomarker for several diseases. For example, it has been shown to be involved in the regulation of NF-kappa signaling, which is a known risk factor for the development of certain diseases, including cancer. Additionally, SIGMAR1 has been shown to be involved in the regulation of cell cycle progression, which is a known risk factor for the development of neurodegenerative diseases.

SIGMAR1 is also a potential drug target for several diseases, including cancer. For example, studies have shown that SIGMAR1 can be targeted by small molecules, such as inhibitors of the NF-kappa pathway, which have been shown to have therapeutic effects in the treatment of cancer. Additionally, SIGMAR1 has been shown to be involved in the regulation of angiogenesis, which is a known risk factor for the development of certain diseases, including cancer.

In conclusion, SIGMAR1 is a gene that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in the NF-kappa pathway and its potential role in the regulation of cellular processes that are relevant to these diseases make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the role of SIGMAR1 in disease and its potential as a drug.

Protein Name: Sigma Non-opioid Intracellular Receptor 1

Functions: Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitter release. Plays a role in calcium signaling through modulation together with ANK2 of the ITP3R-dependent calcium efflux at the endoplasmic reticulum. Plays a role in several other cell functions including proliferation, survival and death. Originally identified for its ability to bind various psychoactive drugs it is involved in learning processes, memory and mood alteration (PubMed:16472803, PubMed:9341151). Necessary for proper mitochondrial axonal transport in motor neurons, in particular the retrograde movement of mitochondria. Plays a role in protecting cells against oxidative stress-induced cell death via its interaction with RNF112 (By similarity)

The "SIGMAR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIGMAR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets